JORDEN POPE

Allopathic & Osteopathic Physicians|Family Medicine EDMOND, OK NPI 1851817407

General Payments — all program years on this page

$354.60

  • Category: General Payments
  • Program years: PY2024
  • Record count: 20
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $354.60 across 20 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $354.6020

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
ABBVIE INC. $115.786
Lilly USA, LLC $58.914
Exact Sciences Corporation $40.032
GlaxoSmithKline, LLC. $34.892
Novo Nordisk AS $33.832
Acerta Pharma LLC $31.142
Lundbeck LLC $23.931
Antares Pharma, Inc. $16.091

By program year

Program yearAmountRecords
2024 $354.6020

Records — PY2024 (20)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1097120635 Novo Nordisk Inc $18.79 12/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097189577 Novo Nordisk Inc $15.04 06/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104208351 AstraZeneca Pharmaceuticals LP $16.37 10/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104431057 AstraZeneca Pharmaceuticals LP $14.77 09/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105293503 ABBVIE INC. $22.92 06/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105293507 ABBVIE INC. $20.94 07/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105293511 ABBVIE INC. $19.19 08/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105293515 ABBVIE INC. $14.65 09/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105293519 ABBVIE INC. $19.51 10/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105293523 ABBVIE INC. $18.57 11/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1114838712 Exact Sciences Corporation $19.87 06/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1114838718 Exact Sciences Corporation $20.16 09/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116021652 GlaxoSmithKline, LLC. $15.70 09/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116321287 GlaxoSmithKline, LLC. $19.19 09/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135073709 Lilly USA, LLC $14.06 07/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135082896 Lilly USA, LLC $14.73 08/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135082898 Lilly USA, LLC $15.70 10/31/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135096726 Lilly USA, LLC $14.42 08/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1145957137 Lundbeck LLC $23.93 11/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1146479449 Antares Pharma, Inc. $16.09 09/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.